Pfizer stock is the stock of an American multinational pharmaceutical and biotechnology corporation. The company is headquartered on 42nd Street in Manhattan and was founded in 1849 by two German entrepreneurs. Charles Pfizer and his cousin, Charles F. Erhart, created a business that would soon be known as Pfizer Inc.
Pfizer stock is trading at less than nine times trailing earnings, which is well below the industry average. Its earnings outlook is also cloudy and the company faces uncertainty for the next year. Pfizer stock is priced below its five-year average, which is also a good indicator that it is undervalued.
Pfizer has a number of projects in the pipeline. As of July, thirty of them were in late-stage trials. It also has ample cash to make acquisitions. With $33 billion on hand and a 3.6% dividend, Pfizer can afford to make major moves. Its stock is still the top player in the healthcare industry, and is a solid buy for those who want to take advantage of a booming business.
Pfizer’s quarterly earnings beat analysts’ estimates and unveiled encouraging results for a vaccine against the respiratory syncytial virus (RSV). While RSV tends to affect infants and the elderly, pregnant women are particularly vulnerable. This vaccine is designed for women, and it has already demonstrated that it is 81% protective against serious RSV for the first 90 days. If approved, it will be the first maternal RSV vaccine.
The company has collaborated with many companies to produce biopharmaceutical medicines for the human health. Its global operations span developed and developing countries and are geared toward advancing wellness. The company was founded in 1849 and is headquartered in New York. For more information, visit pfizer.com/stocks for beginners.
The company’s sales increased last quarter. The Vaccine, Oncology, and Hospital segments led the way. The Rare Diseases and Inflammation & Immunology segments also contributed to the company’s Q2 2022 earnings. However, supply chain constraints and inflationary headwinds may limit earnings growth in the near term.
